Narrow search
Showing 1 - 10 of 75,566
Cover Image
The Economic Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: Can Drugs Ease the Burden?
Murman, Daniel L.; Colenda, Christopher C. - In: PharmacoEconomics 23 (2005) 3, pp. 227-242
The majority of patients with Alzheimer's disease (AD) will have clinically significant neuropsychiatric symptoms during the course of their disease. There is growing evidence that neuropsychiatric symptoms increase direct costs of care in patients with AD, especially the costs associated with...
Persistent link: https://www.econbiz.de/10005449320
Cover Image
Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France
Nuijten, Mark; Hadjadjeba, Lionel; Evans, Christopher; … - In: PharmacoEconomics 14 (1998) 4, pp. 433-445
constructed to model the effectiveness, as measured by time without depression, and the costs of both treatments. The model … favoured fluvoxamine as it was associated with a longer period of time without depression when compared with TCAs (79% of the …
Persistent link: https://www.econbiz.de/10005404792
Cover Image
Depression in the Workplace: Epidemiology, Economics and Effects of Treatment
Russell, James M.; Patterson, James; Baker, Andrew M. - In: Disease Management and Health Outcomes 4 (1998) 3, pp. 135-142
Depression is a common, serious illness that affects millions of individuals, most often in their prime years of … productivity. There is strong evidence that depression is as debilitating as most other general medical conditions and results in … increased general medical resource utilisation. The economic costs of depression are extremely high. The total cost of …
Persistent link: https://www.econbiz.de/10004990298
Cover Image
Reducing the Societal Burden of Depression: A Review of Economic Costs, Quality of Care and Effects of Treatment
Donohue, Julie M.; Pincus, Harold Alan - In: PharmacoEconomics 25 (2007) 1, pp. 7-24
Depression is a highly prevalent condition that results in substantial functional impairment. Advocates have attempted … in recent years to make the `business case' for investing in quality improvement efforts in depression care, particularly … in primary care settings. The business case suggests that the costs of depression treatment may be offset by gains in …
Persistent link: https://www.econbiz.de/10004990342
Cover Image
Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain: The ECOBIM Study
Dilla, Tatiana; Valladares, Amparo; Nicolay, Claudia; … - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 417-430
Background:Background: Weight management is considered a key therapeutic strategy in type 2 diabetes mellitus. However, little is known about the impact of weight loss or body mass index (BMI) reduction on type 2 diabetes-related healthcare costs. Abstract: Objective:Objective: The aim of this...
Persistent link: https://www.econbiz.de/10011005066
Cover Image
Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre
Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777
Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...
Persistent link: https://www.econbiz.de/10011005071
Cover Image
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Ghatnekar, Ola; Hjortsberg, Catharina; Gisslén, Magnus … - In: PharmacoEconomics 28 (2010) S1, pp. 49-57
Introduction: Little is known regarding healthcare costs for HIV/AIDS patients in the era of highly active antiretroviral therapy (HAART) and subgroups of patients according to the severity and progression of HIV infection in Sweden. The objective of this study is therefore to describe the...
Persistent link: https://www.econbiz.de/10011005075
Cover Image
Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting
Dodel, Richard; Happe, Svenja; Peglau, Ines; Mayer, Geert; … - In: PharmacoEconomics 28 (2010) 5, pp. 381-393
addition, the International RLS severity scale (IRLS), Epworth Sleepiness Scale (ESS), EQ-5D and Beck Depression Inventory (BDI …
Persistent link: https://www.econbiz.de/10008620566
Cover Image
Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US
Pike, Crystal; Birnbaum, Howard G.; Schiller, Matt; … - In: PharmacoEconomics 28 (2010) 5, pp. 395-409
Background: Osteoporosis is a condition marked by low bone mineral density and the deterioration of bone tissue. One of the main clinical and economic consequences of osteoporosis is skeletal fractures. Objective: To assess the healthcare and work loss costs of US patients with non-vertebral...
Persistent link: https://www.econbiz.de/10008620567
Cover Image
Economic Burden of Multiple Sclerosis: A Systematic Review of the Literature
Naci, Huseyin; Fleurence, Rachael; Birt, Julie; Duhig, Amy - In: PharmacoEconomics 28 (2010) 5, pp. 363-379
Multiple sclerosis (MS) is a disease of the CNS, typically striking adults during the primary productive time of their life. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient, family, health system...
Persistent link: https://www.econbiz.de/10008620568